A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress

AbCellera Biologics (ABCL) has drawn fresh attention after reporting a narrower quarterly loss than anticipated, supported by a substantial patent litigation settlement that lifted liquidity and coincided with progress across its clinical programs and manufacturing build out.

See our latest analysis for AbCellera Biologics.

The strong 1 day share price return of 12.54% and 7 day share price return of 11.49% around the results suggest investors are reassessing AbCellera’s risks and prospects. However, the 30 day share price return of a 10.03% decline and 3 year total shareholder return of a 56.11% decline show that longer term momentum has faded.

If this update has you looking beyond a single name, it could be a good moment to see what else is happening across 29 healthcare AI stocks as another set of potential ideas in a similar space.

With AbCellera now trading at US$3.59, well below its 3 year total shareholder return, and with around US$700 million in liquidity and multiple clinical milestones ahead, is this a reset entry point or is the market already pricing in future growth?

Most Popular Narrative: 63.5% Undervalued

With AbCellera Biologics closing at $3.59 versus a narrative fair value of $9.83, the current gap between price and expectations is wide enough to deserve a closer look at what is driving that estimate.

The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities.

Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

Read the complete narrative.

Want to see why a company with ongoing losses still lands a much higher fair value? The narrative leans heavily on rapid revenue expansion, rising margins and a premium future earnings multiple. Curious how those pieces fit together over the next few years, and what assumptions have to hold for $9.83 to make sense?

Result: Fair Value of $9.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are real pressure points here, including ongoing net losses and heavy R&D spending, as well as competition around ABCL635 that could challenge the upbeat revenue assumptions.

Find out about the key risks to this AbCellera Biologics narrative.

Another View: Multiples Point to a Very Different Story

That $9.83 narrative fair value paints AbCellera as heavily undervalued, but the current P/S of 14.5x tells a tougher story. It sits well above the US Life Sciences average of 3x, the peer average of 4.3x, and a fair ratio of just 0.3x. This combination suggests meaningful valuation risk if sentiment cools.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution has you uncertain, it is worth checking the numbers yourself and acting while the data is fresh. This includes reviewing 3 important warning signs to see what could matter most for your decision.

Looking for more investment ideas?

If this update has sharpened your thinking, do not stop here. Your next strong move could come from comparing a few different types of opportunities side by side.

• Spot potential bargains quickly by checking companies that screen as 54 high quality undervalued stocks based on their fundamentals and current prices.
• Prioritize resilience by focusing on businesses in the solid balance sheet and fundamentals stocks screener (41 results) that show stronger financial footing and less fragile capital structures.
• Give yourself a shot at earlier stage opportunities by reviewing our screener containing 24 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com